Rather than “playing our cards close to our chest”, we would prefer that every vaccine company, research group, and government agency know exactly what we are doing, why we are doing it that way, what we hope to do next, and what they can expect from us, during the first half of 2025.

          That approach makes the most sense to us, in light of the following factors:

• We do NOT have any facilities, or expertise – or any desire, at any level – to begin testing actual pathogens, in any types of animals. Instead, we are in a “startup incubator lab,” which only allows mice and rats to be tested, and which does not allow any actual pathogens to be tested, used, or brought into the labs.

• We have absolutely no desire to ever become a company which manufactures or sells any type of vaccine. Instead, we hope to become a licensing company, and a company that promotes and enables as much research as possible, as quickly as possible, into as many types of mucosal vaccines as possible, for as many different types of animals as possible. And, those goals and desires are indeed affected by, and consistent with, a set of entirely humanitarian, altruistic, and benevolent hopes and wishes. We want this technology to begin helping people find ways to minimize or completely avoid sickness, suffering, and disease, among animals as well as humans, and we want to do all we can, to help reduce and control healthcare costs.

• Although it is not a pressing goal at the moment, we also hope to eventually help lay a foundation for better, more useful, and more productive exchanges, between anti-vaxxers, and the scientific and medical communities. If these new types of mucosal vaccines can eliminate any need for the harsh and nasty adjuvants that injectable vaccines require, and can provide other important advantages as well, they may end up creating a “middle ground” where people on both sides of the pro-vax and anti-vax arguments can meet, and talk, and actually communicate with each other, rather than pointing fingers, making accusations, and trying to defend against and deny anything and everything “the other side” is doing, to “try to score points”.

 

So . . .  instead of wanting to compete against anyone, we hope to become a licensing company, which can:

• create a structure and system that will incentivize those who are already experts – in testing vaccines against actual pathogens, in one or more types of animals – to do those types of tests. How can we offer that encouragement and incentive? By both: (a) offering, at low cost (our current goal is $2000 for a custom-assembled phage, for at least the first 20 phages), custom-engineered MALT-targeting phage constructs, carrying any antigen sequence that a qualified requester will commit to actually testing, in "pathogen challenge tests"",  in one or more types of animals; and, (b) openly offering a worldwide exclusive license, to any and all use of our MALT-targeting delivery system, for any and all vaccines aganst a specific pathogen or disease, in one or more types of animals, to the first animal vaccine company, vet school research group, or other qualified group which generates “proof of efficacy” that is sufficiently solid and detailed to enable “registration” and authorization, by the U.S. Department of Agriculture, for the requesting company to sell that type of vaccine; and,

• create an advisory board -- if the research in animal vaccines looks strong and promising -- to begin evaluating suggestions and proposals from vaccine manufacturers, for how they would suggest moving forward to begin testing and making MALT-targeting human vaccines against various diseases. In other words, we don’t want to get ahead of ourselves, and we have made no decisions or commitments, of any sort, concerning human vaccines. Instead, if the animal work looks promising, we will begin talking with experienced people who have worked in or with the human vaccine industry, to get their advice, and possibly their support and/or participation.

 

          Stated in alternate words, we hope and intend to create a large number of licensing opportunities, for a substantial number of animal vaccine companies, in ways that (we hope) will end up creating a network of friends, allies, and partners, rather than creating enemies, adversaries, and opponents.